Sleep in Collegiate Baseball Players
Public ClinicalTrials.gov record NCT07212101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Assessing and Optimizing Sleep, Diet, and Performance in Columbia University Baseball Players
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Sleep is an essential biological function that impacts nearly every aspect of an athlete's physical and mental health. For athletes, the importance of high-quality sleep cannot be overstated, as it plays a critical role in performance, recovery, and overall well-being. Sleep supports muscle recovery by promoting protein synthesis and the release of growth hormones, essential for healing after intense physical exertion. Furthermore, adequate sleep is crucial for maintaining cognitive sharpness, decision-making abilities, and emotional regulation-all of which are necessary for optimal athletic performance. The study will assess both sleep quality and quantity in baseball players at Columbia University. These tools will help quantify key sleep metrics, including sleep duration, latency (the time it takes to fall asleep), and the number of awakenings during the night. Similarly, the study will analyze dietary patterns using the Automated Self-Administered 24-Hour Dietary Assessment (ASA24), tracking nutrient intake, meal timing, and the consumption of ultra-processed foods. These assessments will establish a baseline from which to measure improvement post-intervention. The intervention will focus on improving diet, time in bed, and light exposure to improve sleep, diet, and performance in collegiate baseball athletes.
Study identification
- NCT ID
- NCT07212101
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2025
- Primary completion
- Oct 30, 2025
- Completion
- Oct 30, 2025
- Last update posted
- Dec 17, 2025
2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07212101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07212101 live on ClinicalTrials.gov.